AbbVie (NYSE:ABBV) Releases Earnings Results, Beats Expectations By $0.06 EPS

AbbVie (NYSE:ABBV) released its quarterly earnings data on Wednesday. The company reported $2.71 EPS for the quarter, topping the consensus estimate of $2.65 by $0.06, FiscalAI reports. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The company had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. During the same period last year, the firm earned $2.16 EPS. AbbVie’s revenue for the quarter was up 10.0% on a year-over-year basis. AbbVie updated its FY 2026 guidance to 14.370-14.570 EPS and its Q1 2026 guidance to 2.970-3.010 EPS.

Here are the key takeaways from AbbVie’s conference call:

• AbbVie reported a record FY2025 with $61.2B in revenue and adjusted EPS of $10, and guided 2026 revenue to approximately $67B (+9.5%) with adjusted EPS of $14.37–$14.57, above prior expectations.
• Management said Skyrizi and Rinvoq are the primary growth engines — combined sales already eclipsing $25.9B in 2025 and projected to exceed $31B in 2026, driven by strong share capture in psoriasis and IBD.
• AbbVie increased R&D spending and invested heavily in BD (>$5B), adding early‑stage and platform assets — including an in vivo CAR‑T, psychedelic (bretisilocin), trispecific antibodies, a long‑acting amylin analog, and an siRNA platform — to broaden future growth opportunities.
• Persistent headwinds include ongoing Humira erosion (nearly $16B since LOE) and expected Imbruvica IRA pricing pressure, which management says will unfavorably affect oncology growth in 2026.
• AbbVie announced a voluntary U.S. agreement to expand patient access (Medicaid pricing, direct cash‑pay options) while committing $100B in U.S. R&D and capital over the next decade, a move management presents as balancing affordability and protection of innovation.

AbbVie Stock Performance

Shares of ABBV opened at $217.04 on Thursday. AbbVie has a fifty-two week low of $164.39 and a fifty-two week high of $244.81. The firm has a market cap of $383.59 billion, a price-to-earnings ratio of 164.42, a PEG ratio of 0.93 and a beta of 0.35. The firm has a 50 day moving average price of $223.99 and a 200-day moving average price of $219.14.

Institutional Trading of AbbVie

Several hedge funds have recently added to or reduced their stakes in ABBV. Quarry LP purchased a new position in shares of AbbVie in the third quarter worth about $41,000. Rakuten Securities Inc. boosted its holdings in AbbVie by 26.5% during the 2nd quarter. Rakuten Securities Inc. now owns 368 shares of the company’s stock valued at $68,000 after acquiring an additional 77 shares during the period. Binnacle Investments Inc grew its position in AbbVie by 33.2% during the 2nd quarter. Binnacle Investments Inc now owns 493 shares of the company’s stock worth $92,000 after acquiring an additional 123 shares during the last quarter. Triumph Capital Management purchased a new position in AbbVie in the 3rd quarter worth approximately $193,000. Finally, Wealth Watch Advisors INC bought a new stake in AbbVie in the third quarter valued at approximately $210,000. 70.23% of the stock is owned by institutional investors.

Analysts Set New Price Targets

ABBV has been the topic of a number of recent research reports. BMO Capital Markets reissued an “outperform” rating and set a $258.00 price objective on shares of AbbVie in a report on Thursday, January 15th. Berenberg Bank set a $275.00 price target on AbbVie in a research report on Tuesday, January 20th. Cantor Fitzgerald set a $250.00 price objective on shares of AbbVie and gave the company an “overweight” rating in a research report on Thursday, October 9th. Hsbc Global Res raised shares of AbbVie from a “hold” rating to a “strong-buy” rating in a report on Wednesday, December 10th. Finally, Scotiabank assumed coverage on shares of AbbVie in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 target price on the stock. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $251.50.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q4 beat on top and bottom line — AbbVie reported adjusted EPS of $2.71 (above consensus) and revenue of $16.62B, driven by overall revenue strength and margin expansion; this underpins the company’s raised annual outlook. AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results
• Positive Sentiment: Skyrizi and Rinvoq are driving growth — both drugs grew >30% Y/Y and powered immunology revenue, helping offset Humira declines and supporting the bullish FY profit outlook. Strong uptake is a core reason management lifted 2026 profit guidance. AbbVie forecasts 2026 profit above estimates
• Positive Sentiment: Rinvoq expansion opportunity — AbbVie has filed for upadacitinib (Rinvoq) approval in vitiligo with FDA/EMA; a new indication would expand addressable market and is a potential medium-term revenue kicker. AbbVie submits regulatory applications for Rinvoq in vitiligo
• Neutral Sentiment: 2026 adjusted EPS guidance raised but caveated — management set FY 2026 adjusted EPS at $14.37–$14.57 (above consensus), which is supportive, but the range excludes acquired IPR&D and milestone costs (management warns these items are unpredictable). Full Q4 release and 2026 guidance
• Negative Sentiment: Softer Q1 2026 guide sparked the selloff — AbbVie trimmed Q1 EPS and revenue guidance (Q1 EPS range 2.97–3.01 vs. a higher consensus), and the lower near-term guide appears to be the main catalyst for today’s decline. AbbVie beats Q4; stock down despite upbeat ’26 view
• Negative Sentiment: Concerns about diversification and aesthetics/oncology weakness — investors and some analysts flagged that outside immunology (Skyrizi/Rinvoq) growth is uneven (aesthetics down ~6% FY, oncology pressure), raising questions about longer-term growth without more M&A or new launches. That debate is weighing on sentiment. AbbVie diversification concerns (Seeking Alpha)

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.